Literature DB >> 11205430

Synergistic efects of opioid and cannabinoid antagonists on food intake.

T C Kirkham1, C M Williams.   

Abstract

RATIONALE: Central cannabinoid systems have been implicated in appetite regulation through the hyperphagic effects of exogenous and endogenous cannabinoids. These effects may involve activation of reward systems and be mediated in part by opioidergic processes.
OBJECTIVE: Cannabinoid-opioid interactions in feeding were examined by testing the combined effects on food intake of sub-anorectic doses of selective antagonists for CB1 and opioid receptors.
METHODS: Male rats (n = 8) received subcutaneous injections of naloxone (0, 0.1, 0.5, 1.0 mg/kg) and SR141716 (0, 0.1, 0.5, 1.0 mg/kg) before l-h, nocturnal food (chow) intake tests.
RESULTS: Neither naloxone nor SR141716 reliably affected feeding when administered alone. By contrast, combined administration of the two antagonists significantly suppressed chow intake at each dose combination. Joint administration of the highest doses of each antagonist suppressed intake by 73%, a significantly greater effect than produced by either naloxone (32%) or SR141716 alone (17%).
CONCLUSION: The data reveal a synergistic interaction between the effects of naloxone and SR141716 on feeding, provide further evidence of important functional relationships between endogenous cannabinoid and opioid systems, and strengthen the postulated role for endocannabinoids in reward processes contributing to the normal control of appetite.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11205430     DOI: 10.1007/s002130000596

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

Authors:  Aaron N A Verty; Malini E Singh; Iain S McGregor; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2003-04-17       Impact factor: 4.530

Review 2.  The endocannabinoid system: role in energy regulation.

Authors:  Thomas F Gamage; Aron H Lichtman
Journal:  Pediatr Blood Cancer       Date:  2012-01       Impact factor: 3.167

3.  Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.

Authors:  Jason E Gallate; Paul E Mallet; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

4.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

5.  Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

6.  The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food.

Authors:  Zoë D Thornton-Jones; Steven P Vickers; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

7.  A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour.

Authors:  Zoë D Thornton-Jones; Guy A Kennett; Steven P Vickers; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2007-03-20       Impact factor: 4.530

Review 8.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

9.  Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward.

Authors:  David J Rademacher; Cecilia J Hillard
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-12-28       Impact factor: 5.067

10.  Reduced sensitivity to reward in CB1 knockout mice.

Authors:  Carles Sanchis-Segura; Brandon H Cline; Giovanni Marsicano; Beat Lutz; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.